AATRU Clinical Trials
Our clinical trials are funded by the NIH and Pharma and focus on understanding the origins of asthma, how we can decrease asthma morbidity and mortality using translational methods and development and testing of new biologics for precision based individualized medicine.
In 2020, we expanded our research unit in response to the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to the COVID-19 pandemic to evaluate prevention and treatment of this infection. We currently have >25 ongoing studies, all of which have opportunities for enrollment, research and collaboration.
Interested in Enrolling in a Clinical Study?
complete the clinical study interest form
Information on current studies may be found by choosing a title below:
MATCH
Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma.
- Enrollment Status: Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Sponsors: Johns Hopkins University, Nemours Children's Health System, American Lung Association & National Heart, Lung, and Blood Institute (NHLBI)
- PI: Mario Castro, MD, MPH
RELIANCE
A multi-center, randomized, 48-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of 500 mcg QD or alternate regimen of roflumilast (Daliresp) therapy versus 250 mg QD, 500 mg QD three times per week, or alternate regimen of azithromycin therapy to prevent COPD exacerbations.
- Enrollment Status: Recruiting
- Study Type: Interventional (Clinical Trial)
- Sponsors: Johns Hopkins University, Patient-Centered Outcomes Research Institute
- PI: Mario Castro, MD, MPH
Lung Health Cohort (LHC)
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
- Enrollment Status: Recruiting
- Study Type: Observational
- Sponsors: Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
- PI: Mario Castro, MD, MPH
PreCISE
PrecISE is an NHLBI-sponsored network established to conduct a phase 2 proof-of-concept study to test interventions in biomarker-defined subgroups of patients with severe asthma.
- Enrollment Status: Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Sponsors: University of North Carolina-Chapel Hill & National Heart, Lung, and Blood Institute (NHLBI)
- PI: Mario Castro, MD, MPH
SARP-4
The mission of the SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.
- Enrollment Status: Closed to Enrollment
- Study Type: Observational
- Sponsors: Milton S. Hershey Medical Center & National Heart, Lung, and Blood Institute (NHLBI)
- PI: Mario Castro, MD, MPH
Chinook
A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics.
- Enrollment Status: Recruiting
- Study Type: Interventional (Clinical Trial)
- Sponsor: AstraZeneca AB
- PI: Mario Castro, MD, MPH
Oberon
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations.
- Enrollment Status: Recruiting
- Study Type: Interventional (Clinical Trial)
- Sponsor: AstraZeneca
- PI: Mario Castro, MD, MPH
Resolute
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils.
- Enrollment Status: Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Sponsor: AstraZeneca
- PI: Mario Castro, MD, MPH
RheSolve
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD.
- Enrollment Status: Closed to enrollment
- Study Type: Interventional (Clinical Trial)
- Sponsor: Gala Therapeutics, Inc.
- PI: Mario Castro, MD, MPH
Sanofi_DRI17509
A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma.
- Enrollment Status: Closed to enrollment
- Study Type: Interventional (Clinical Trial)
- Sponsor: Sanofi
- PI: Mario Castro, MD, MPH
Aerify-3
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPD.
- Enrollment Status: Recruiting
- Study Type: Interventional (Clinical Trial)
- Sponsor: Sanofi
- PI: Mario Castro, MD, MPH
Flair
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma
- Enrollment Status: Recruiting
- Study Type: Interventional (Clinical Trial)
- Sponsor: Teva Branded Pharmaceutical Products R&D Inc.
- PI: Mario Castro, MD, MPH
AATRU Bronchoscopy Biobank
- Enrollment Status: Recruiting
- Study Type: Observational
- PI: Mario Castro, MD, MPH
AATRU Biobank
- Enrollment Status: Recruiting
- Study Type: Observational
- PI: Mario Castro, MD, MPH
Dupilumab IIS
- Enrollment Status: N/A
- Study Type: Closed to Enrollment
- Sponsor: Regeneron
- PI: Navneet Kaur Dhillon, PhD
- ABPA Asthma
- ALA ABBS
- ALA ABBS
- ALA LEEP
- APW-RSV II
- Asthma EV
- CoVPN D8110C00001
- Novartis CSJ117A12201C
- PCORnet HERO HCQ
- Regeneron R668-AS-1903
- Reliance (Phase 1)
- Shinogi Cough
- TEVA TV48574-AS-20031
- Theravance TD-4208-0192
- Vestige LPS15834
